Impact of specific immunotherapy and sting challenge on the quality of life in patients with hymenoptera venom allergy

被引:11
|
作者
Eitel, Tamara [1 ]
Zeiner, Kim Nikola [1 ]
Assmus, Katharina [1 ]
Ackermann, Hanns [2 ]
Zoeller, Nadja [1 ]
Meissner, Markus [1 ]
Kaufmann, Roland [1 ]
Kippenberger, Stefan [1 ]
Valesky, Eva Maria [1 ]
机构
[1] Goethe Univ Frankfurt, Dept Dermatol Venereol & Allergol, Frankfurt, Germany
[2] Goethe Univ Frankfurt, Dept Biostat & Math Models, Frankfurt, Germany
来源
WORLD ALLERGY ORGANIZATION JOURNAL | 2021年 / 14卷 / 05期
关键词
Hymenoptera venom allergy; Immunotherapy; Sting challenge; Quality of life; DEBILITATING BELIEFS; EMOTIONAL DISTRESS; HOSPITAL ANXIETY; DEPRESSION SCALE; INSECT; EPIDEMIOLOGY; VERSION; HADS;
D O I
10.1016/j.waojou.2021.100536
中图分类号
R392 [医学免疫学];
学科分类号
100102 ;
摘要
Background: An experienced life-threating anaphylactic reaction to hymenoptera venom can sustainably impair patients' quality of life (QoL). Besides carrying emergency medication, venom specific immunotherapy (VIT) exists as a causal treatment of allergy. Objective: This study aimed to examine QoL, anxiety, depression, and physical and mental health in patients allergic to hymenoptera venom before and during VIT and the impact of a tolerated sting challenge (SC). Methods: Between July 2017 and August 2017, 142 patients with venom allergy were analyzed using validated questionnaires as the: Vespid Allergy Quality for Life Questionnaire" (VQLQ-d), the "Hospital Anxiety and Depression Scale" (HADS-D) and the "Short Form 36" (SF-36).To evaluate the impact of VIT and SC on the QoL, patients were divided into 3 groups: (A) VIT and tolerated SC (n =45), (B) VIT before carrying out SC (n = 73), and (C) therapy-na & iuml;ve before VIT (n = 20). Further parameters like gender, age, insect species, and severity of the anaphylactic reaction were assessed. Results: A significant correlation between the health-related QoL and the parameters of gender and state of treatment was seen. Especially male patients, as well as patients allergic to yellow jacket venom, benefit from a SC in terms of a significant increase in their QoL. In the total study cohort, a clear trend was observed towards a higher QoL in patients under VIT who tolerated a SC. Overall, neither the patients' age nor the insect species exerted a relevant influence on QoL, depression or anxiety. However, women showed a lower QoL combined with higher anxiety and depression scores than men. Conclusion: Immunotherapy leads to an improved QoL, which can be further increased by a SC. A tolerated SC conceivably reassures the patients by objectifying the treatment success. Female patients appear to have a stronger impaired QoL per se. Taken together, a SC can be performed during VIT to strengthen the patients' QoL.
引用
收藏
页数:13
相关论文
共 50 条
  • [1] Hymenoptera sting challenge test in patients with allergy to venom vespids
    Anguita Carazo, J.
    Galvez Lozano, J.
    Alcantara Villar, M.
    Lopez-Urbano, M.
    Mayorgas Costoya, R.
    Saenz de San Pedro, Morera B.
    Quiralte Enriquez, J.
    ALLERGY, 2008, 63 : 441 - 441
  • [2] The sting challenge test in Hymenoptera venom allergy
    Rueff, F
    Przybilla, B
    Muller, U
    Mosbech, H
    ALLERGY, 1996, 51 (04) : 216 - 225
  • [3] Safety of sting challenge tests in patients receiving Hymenoptera venom immunotherapy
    Kroth, J.
    Linhardt, A.
    Przybilla, B.
    Rueff, F.
    ALLERGY, 2010, 65 : 100 - 100
  • [4] Quality of life in patients allergic to Hymenoptera venom who refuse specific immunotherapy
    Mikulski, Damian
    Smorawska-Sabanty, Ewa
    Kowalski, Marek L.
    ALERGIA ASTMA IMMUNOLOGIA, 2016, 21 (02): : 133 - 137
  • [5] Effect of venom immunotherapy and sting challenge on HRQoL measured by venom-allergy quality of life questionnaire (VQLQ) in Jack jumper ant allergic patients
    Spriggs, Kymble
    Leahy, Elizabeth
    Weibel, Nicole
    Barnes, Sara
    ALLERGY, 2024,
  • [6] Usefulness of Omalizumab and Sting Challenge Test in Hymenoptera Venom Allergy and Mastocytosis
    Gonzalez-de-Olano, D.
    Padial-Vilchez, M. A.
    Nunez-Acevedo, B.
    de-Calzada-Bustingorri, M. P.
    de-Andres-Martin, A.
    Caldas, C.
    Piris-Villaespesa, M.
    de-la-Hoz-Caballer, B.
    JOURNAL OF INVESTIGATIONAL ALLERGOLOGY AND CLINICAL IMMUNOLOGY, 2019, 29 (04) : 318 - 320
  • [7] Tolerated Sting Challenge in Patients on Hymenoptera Venom lmmunotherapy Improves Health-Related Quality of Life
    Kosche, D. S.
    Schmies, M.
    Weber, C. Nink
    Hoeffken, G.
    Balck, F.
    JOURNAL OF INVESTIGATIONAL ALLERGOLOGY AND CLINICAL IMMUNOLOGY, 2014, 24 (04) : 226 - 230
  • [8] Impact of immunotherapy on blood dendritic cells in patients with Hymenoptera venom allergy
    Dreschler, Katharina
    Bratke, Kai
    Petermann, Sebastian
    Bier, Andrea
    Thamm, Petra
    Kuepper, Michael
    Virchow, J. Christian
    Lommatzsch, Marek
    JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2011, 127 (02) : 487 - U1820
  • [9] Sublingual immunotherapy with venom is not recommended for patients with Hymenoptera venom allergy
    Rueff, Franziska
    Bilo, M. Beatrice
    Jutel, Marek
    Mosbech, Holger
    Mueller, Ulrich
    Przybilla, Bernhard
    JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2009, 123 (01) : 272 - 273
  • [10] Sublingual immunotherapy with venom for patients with Hymenoptera venom allergy Reply
    Rueff, Franziska
    Bilo, M. Beatrice
    Jutel, Marek
    Mosbech, Holger
    Mueller, Ulrich
    Kuechenhoff, Helmut
    Przybilla, Bernhard
    JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2009, 124 (02) : 385 - 386